These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 10440447)

  • 1. A one year experience: T cell responses and viral replication in children with advanced human immunodeficiency virus type 1 disease treated with combination therapy including ritonavir.
    Pelton SI; Johnson D; Chadwick E; Baldwin Z; Yogev R
    Pediatr Infect Dis J; 1999 Jul; 18(7):650-2. PubMed ID: 10440447
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination antiretroviral therapy including ritonavir in children infected with human immunodeficiency.
    Thuret I; Michel G; Chambost H; Tamalet C; Giraud P; Brunet C; Perrimond H
    AIDS; 1999 Jan; 13(1):81-7. PubMed ID: 10207548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages.
    Sleasman JW; Nelson RP; Goodenow MM; Wilfret D; Hutson A; Baseler M; Zuckerman J; Pizzo PA; Mueller BU
    J Pediatr; 1999 May; 134(5):597-606. PubMed ID: 10228296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD8+ lymphocyte responses to antiretroviral therapy of HIV infection.
    Carr A; Emery S; Kelleher A; Law M; Cooper DA
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Dec; 13(4):320-6. PubMed ID: 8948369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.
    Lederman MM; Connick E; Landay A; Kuritzkes DR; Spritzler J; St Clair M; Kotzin BL; Fox L; Chiozzi MH; Leonard JM; Rousseau F; Wade M; Roe JD; Martinez A; Kessler H
    J Infect Dis; 1998 Jul; 178(1):70-9. PubMed ID: 9652425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.
    Autran B; Carcelain G; Li TS; Blanc C; Mathez D; Tubiana R; Katlama C; Debré P; Leibowitch J
    Science; 1997 Jul; 277(5322):112-6. PubMed ID: 9204894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy.
    Jubault V; Burgard M; Le Corfec E; Costagliola D; Rouzioux C; Viard JP
    AIDS; 1998 Dec; 12(17):2358-9. PubMed ID: 9863885
    [No Abstract]   [Full Text] [Related]  

  • 8. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.
    Nachman SA; Stanley K; Yogev R; Pelton S; Wiznia A; Lee S; Mofenson L; Fiscus S; Rathore M; Jimenez E; Borkowsky W; Pitt J; Smith ME; Wells B; McIntosh K
    JAMA; 2000 Jan; 283(4):492-8. PubMed ID: 10659875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residual HIV-1 replication may impact immune recovery in patients on first-line lopinavir/ritonavir monotherapy.
    Tran TA; Ghosn J; Avettand-Fenoël V; Hendel-Chavez H; de Goër de Herve MG; Cohen-Codar I; Rouzioux C; Delfraissy JF; Taoufik Y
    J Antimicrob Chemother; 2015 Sep; 70(9):2627-31. PubMed ID: 26023212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
    García F; Plana M; Vidal C; Cruceta A; O'Brien WA; Pantaleo G; Pumarola T; Gallart T; Miró JM; Gatell JM
    AIDS; 1999 Jul; 13(11):F79-86. PubMed ID: 10449278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ritonavir and saquinavir combination therapy for the treatment of HIV infection.
    Cameron DW; Japour AJ; Xu Y; Hsu A; Mellors J; Farthing C; Cohen C; Poretz D; Markowitz M; Follansbee S; Angel JB; McMahon D; Ho D; Devanarayan V; Rode R; Salgo M; Kempf DJ; Granneman R; Leonard JM; Sun E
    AIDS; 1999 Feb; 13(2):213-24. PubMed ID: 10202827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protease inhibitor and triple-drug therapy: cellular immune parameters are not restored in pediatric AIDS patients after 6 months of treatment.
    Chougnet C; Fowke KR; Mueller BU; Smith S; Zuckerman J; Jankelevitch S; Steinberg SM; Luban N; Pizzo PA; Shearer GM
    AIDS; 1998 Dec; 12(18):2397-406. PubMed ID: 9875577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.
    De Luca M; Miccinesi G; Chiappini E; Zappa M; Galli L; De Martino M
    Int J Immunopathol Pharmacol; 2005; 18(4):729-35. PubMed ID: 16388722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.
    Arribas JR; Girard PM; Landman R; Pich J; Mallolas J; Martínez-Rebollar M; Zamora FX; Estrada V; Crespo M; Podzamczer D; Portilla J; Dronda F; Iribarren JA; Domingo P; Pulido F; Montero M; Knobel H; Cabié A; Weiss L; Gatell JM;
    Lancet Infect Dis; 2015 Jul; 15(7):785-92. PubMed ID: 26062880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.
    Murphy RL; Brun S; Hicks C; Eron JJ; Gulick R; King M; White AC; Benson C; Thompson M; Kessler HA; Hammer S; Bertz R; Hsu A; Japour A; Sun E
    AIDS; 2001 Jan; 15(1):F1-9. PubMed ID: 11192874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ritonavir-boosted lopinavir monotherapy due to intolerance to nucleoside reverse transcriptase inhibitors in an HIV-infected paediatric patient].
    Espiau M; Soler-Palacín P; Borrull A; Figueras C
    Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):319. PubMed ID: 21334110
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014.
    Rojas Sánchez P; Prieto L; Jiménez De Ory S; Fernández Cooke E; Navarro ML; Ramos JT; Holguín Á;
    PLoS One; 2017; 12(3):e0173168. PubMed ID: 28350802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amping amprenavir with ritonavir.
    TreatmentUpdate; 2001; 12(12):10. PubMed ID: 11570075
    [No Abstract]   [Full Text] [Related]  

  • 20. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo.
    Markowitz M; Louie M; Hurley A; Sun E; Di Mascio M; Perelson AS; Ho DD
    J Virol; 2003 Apr; 77(8):5037-8. PubMed ID: 12663814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.